Methods | We analyzed the June 2016 Centers for Medicare and Medicaid Services Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information Files for all Part D plans except special-needs plans that may have specialized formularies. Files contained drug benefit design data (formularies and copayment requirements) and not patient claims. We examined out-of-pocket cost requirements for PCSK9is (alirocumab and evolocumab) averaged across all plans by counties and states.
We projected annual out-of-pocket costs under a standard 2016 Medicare Part D benefit for beneficiaries receiving a PCSK9i and generic atorvastatin 80 mg but no other drugs. We sequentially included (1) an initial $360 deductible; (2) a coverage phase in which out-of-pocket costs were estimated from mean cost-sharing requirements nationwide for PCSK9is and atorvastatin; (3) a coverage gap (donut hole) once total drug costs reached $3310, with cost-sharing increasing to 45% for brand-name drugs and 58% for generic drugs; and (4) catastrophic coverage when out-of-pocket costs exceeded $4850, reducing cost-sharing to 5% for the remainder of the year.
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The University of Hawaii Office of Research Compliance provided the institutional review board waiver, and patient consent was waived.
Results | We analyzed 2575 Part D plans across 50 states and the District of Columbia. In mid-2016, 88% of plans covered PCSK9is (87% covered alirocumab and 42% covered evolocumab) (Table) . Mean (SD) required cost-sharing for a 30-day supply was $336 ($3) for alirocumab, $321 ($8) for evolocumab, and $4 ($1) for atorvastatin. Under a standard 2016 Part D plan, beneficiaries receiving a PCSK9i and atorvastatin would have reached the coverage gap by March (Figure) , with projected annual out-of-pocket costs of $4997 for alirocumab/ atorvastatin and $4968 for evolucumab/atorvastatin (Table) . This represented approximately one-third the annual total costs ($14 330 for alirocumab/atorvastatin and $13 760 for evolocumab/atorvastatin).
Discussion | Nearly 9 in 10 Medicare Part D plans nationwide cover PCSK9is. However, affordability is of substantial concern: mean cost-sharing requirements exceeded $300 per month, and projected annual out-of-pocket costs approached (21) 4000 (29) 1886 (14) Abbreviations: OOP, out-of-pocket; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor. a Averaged across all plans in a county, then across all counties and states.
b During initial coverage phase, ie, after deductible met and before coverage gap. c Deductible of $360, coverage gap starting at $3310 in total drug costs (during gap, beneficiaries are responsible for 45% coinsurance for brand-name drugs, plans are responsible for 5%, and pharmaceutical manufacture discount accounts for 50% of the cost), and catastrophic coverage starting at $4850 in out-of-pocket expenditures (beneficiaries are responsible for 5% of total drug cost, plans cover 15%, and Medicare 80%). d Total drug costs and percentages may not add up to 100% owing to rounding.
e Of the plans that cover PCSK9is, 97% require prior authorization.
f All plans covered generic atorvastatin 80 mg without prior authorization, with a mean (SD) out-of-pocket cost of $4 ($1) and total drug cost of $13 ($2) per 30-day prescription.
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$5000 under a standard 2016 Part D benefit. Because costsharing can reduce adherence even for less expensive statins, 3 the effect of these high out-of-pocket costs on adherence and real-world effectiveness warrants examination. We estimate that beneficiaries would pay one-third of PCSK9i costs under a standard 2016 Part D plan if they filled prescriptions for PCSK9i and atorvastatin and no other medications. Prior efforts to improve drug affordability have been aimed at decreasing the percentage of cost-sharing by beneficiaries. 5, 6 The Affordable Care Act will reduce costsharing for brand-name drugs during the coverage gap to 25% by 2020. 5 While this might work for cheaper drugs, the high price of PCSK9i indicates that lower coinsurance rates could still result in thousands of dollars in out-of-pocket costs annually.
Limitations. We projected annual cost-sharing based only on PCSK9i and atorvastatin use. Actual out-of-pocket costs would reflect a beneficiary's coverage phase when filling each prescription, which in turn is affected by their non-PCSK9i medication use.
Conclusions | Our findings suggest a need to lower out-ofpocket costs to ensure affordability of PCSK9is for Medicare beneficiaries covered by Part D.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Under a standard 2016 Medicare Part D drug benefit, Medicare beneficiaries start each year with a $360 deductible. This is followed by the initial coverage phase, with out-of-pocket costs determined by a plan's cost-sharing requirements for covered drugs. Once total drug costs reach $3310, beneficiaries enter the coverage gap or "donut hole," in which they are responsible for greater cost-sharing (45% for brand-name drugs [PCSK9 inhibitors] and 58% for generic drugs [atorvastatin] ). If out-of-pocket costs reach $4850, catastrophic coverage takes effect, reducing cost-sharing to 5% for the remainder of the year. We accounted for each of these coverage phases in our projections of PCSK9i cost-sharing. Standard deviations on the estimated mean monthly out-of-pocket costs range from $1 to $8. rettes (e-cigarettes) are associated with increased cardiovascular risk. To reach this conclusion, the authors measured the heart rate variability, an index of sympathovagal modulation, and 3 parameters of oxidative stress, ie, low-density lipoprotein oxidizability, high-density lipoprotein antioxidant/ anti-inflammatory capacity, and paraoxonase-1 activity, in the plasma of e-cigarettes smokers and nonsmokers. 1 Notably, physical activity, or exercise training (both terms are usually used interchangeably), has important effects on sympathovagal activity and oxidative stress, 2 mechanisms analyzed by the authors. Most importantly, the changes induced by shortterm or long-term exercise training on these parameters are substantially different. The reduction of parasympathetic influence after short-term exercise has been demonstrated using heart rate variability, showing a gradual reduction in highfrequency power paralleling increased exercise intensity, 2 while long-term exercise-trained individuals have increased heart rate variability as well as improved baroreflex responsiveness.
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On the other hand, short-term exercise bouts considerably increase oxidative stress, wherein trained individuals show an enhanced endogenous antioxidant enzyme capacity and an increased tolerance to exercise-induced oxidative stress. 4 Likewise, sedentary lifestyle is also associated with increased oxidative stress 5 and negatively affects heart rate variability. In fact, it has been reported that a sedentary lifestyle is as hazardous as smoking in terms of cardiovascular risk. Intriguingly, the authors do not report any observation in reference to exercising habits in both e-cigarette smokers and nonsmokers. This might importantly bias the results of specific parameters evaluated in any single group or even in both groups. It is well known that nonsmoking is associated with increased habitual exercise and vice versa. We absolutely do not advocate smoking, either regular or e-cigarettes, and strongly advise against it. However, the parameters analyzed in this study are probably not the most appropriate for studying the increased cardiovascular risk associated with the use of e-cigarettes unless confounding variables are strictly considered in the analysis.
